VYNE — Vyne Therapeutics Share Price
0.000.00%
Last trade - 00:00- $19.77m
- -$0.15m
- $0.50m
- 37
- 29
- 42
- 28
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | 0.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 39.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -83.78% | ||
| Return on Equity | -56.54% | ||
| Operating Margin | -8709.98% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 20.99 | 0.93 | 0.48 | 0.42 | 0.5 | 0.2 | 0.2 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
Directors
- David Domzalski PRE (54)
- Tyler Zeronda CFO
- Garrett Galley CTO
- Iain Stuart CSO (48)
- Mutya Harsch GCN (46)
- Matthew Wiley OTH (49)
- Patrick Lepore LED (66)
- Steven Basta DRC (54)
- Sharon Barbari IND (66)
- Anthony Bruno IND (64)
- Elisabeth Sandoval IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 21st, 2011
- Public Since
- January 25th, 2018
- No. of Shareholders
- 8
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 16,664,892
- Address
- 685 Route 202/206 N., Suite 301, BRIDGEWATER, 08807
- Web
- https://vynetherapeutics.com/
- Phone
- +1 6504861416
- Auditors
- BAKER TILLY US LLP
Upcoming Events for VYNE
Q3 2025 Vyne Therapeutics Inc Earnings Release
Similar to VYNE
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Vyne Therapeutics share price?
As of Today at 24:02 UTC, shares in Vyne Therapeutics are trading at $1.30. This share price information is delayed by 15 minutes.
How has the Vyne Therapeutics share price performed this year?
Shares in Vyne Therapeutics last closed at $1.30 and the price had moved by -50.94% over the past 365 days. In terms of relative price strength the Vyne Therapeutics share price has underperformed the S&P500 Index by -54.73% over the past year.
What are the analyst and broker recommendations for Vyne Therapeutics?
The overall consensus recommendation for Vyne Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Vyne Therapeutics dividend yield?
Vyne Therapeutics does not currently pay a dividend.
Does Vyne Therapeutics pay a dividend?
Vyne Therapeutics does not currently pay a dividend.
When does Vyne Therapeutics next pay dividends?
Vyne Therapeutics does not currently pay a dividend.
How do I buy Vyne Therapeutics shares?
To buy shares in Vyne Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vyne Therapeutics?
As of the previous close price of $1.30, shares in Vyne Therapeutics had a market capitalisation of $19.77m.
Where are Vyne Therapeutics shares listed?
Here are the trading details for Vyne Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: VYNE
What kind of share is Vyne Therapeutics?
Based on an overall assessment of its quality, value and momentum Vyne Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vyne Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Vyne Therapeutics is $6.38. That is 390.77% above the last closing price of $1.30.
Analysts covering Vyne Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.23 for the next financial year.
Find out moreWhat is the trend in the Vyne Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vyne Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -56.38%.
As of the last closing price of $1.30, shares in Vyne Therapeutics were trading -41.91% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vyne Therapeutics PE Ratio?
The Vyne Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vyne Therapeutics?
Vyne Therapeutics' management team is headed by:
- David Domzalski - PRE
- Tyler Zeronda - CFO
- Garrett Galley - CTO
- Iain Stuart - CSO
- Mutya Harsch - GCN
- Matthew Wiley - OTH
- Patrick Lepore - LED
- Steven Basta - DRC
- Sharon Barbari - IND
- Anthony Bruno - IND
- Elisabeth Sandoval - IND